You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
神州細胞(688520.SH):14價HPV疫苗SCT1000正在開展Ⅲ期臨牀研究
格隆匯 12-29 09:41

格隆匯12月29日丨神州細胞(688520.SH)投資者關係活動記錄表顯示,前三季度營業收入超過13.79億元,同比增長112.08%,主要還是來自於重組八因子安佳因®銷售收入的持續增長。前三季度歸屬於上市公司股東的淨虧損約2.20億元,虧損同比縮小45.37%,虧損大幅收窄。前三季度公司總體研發投入約8.65億,同比增長30.70%,佔營業收入的比例達到62.69%。

產品方面,2023年初至今,公司兩個生物類似藥阿達木單抗產品安佳潤®和貝伐珠單抗產品安貝珠®已於2023年6月先後獲批上市。已上市的瑞帕妥單抗注射液安平希®也於近期成功納入2023年國家醫保目錄。公司針對XBB/BQ1.1等變異株的4價迭代新冠疫苗SCTV01E-2已於2023年12月在國內被納入緊急使用。菲諾利單抗注射液(PD-1單抗)的頭頸部鱗狀細胞癌適應症的上市申請已獲受理。14價HPV疫苗SCT1000正在開展Ⅲ期臨牀研究。IL-17單克隆抗體注射液SCT650C已在澳大利亞開展Ia期臨牀研究。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account